The study realized on 66 chronic hepatitis B patients over 16 years of age with HBeAg(-) treated by Tenofovir Disoproxyl Furamate in 48 weeks. Patients and method: 66 chronic HBV with HBeAg(-). Criteria of diagnostic based on the APASAL Guidlines 2009, HBV DNA dosage by PCR real time of Tagman with the threshold negative 200 copies/L. The drug in use: Tenofovir (Getino B) 300mg/day. Asessement the clinical, enzyme transaminase, bilirubinemia and HBVDNA each 12Wks. Results: The clinical signs diminue rapidly: asthenia drop from 10 percent to 1,5 percent after 12 weeks and 0 percent after 24 weeks. Lost appetite from 13,6 percent, and jaundice from 12,1 percent to 0 percent after 12 weeks. The response of hepatic size is slow and small, only from 16,7 percent to 15,2 percent at the 24 week then 12,1 percent at the end of 48th week. The mean virus load (HBV DNA) before the treatment: 6,81 + or - 1, 36)log copies/mL and after 48 weeks of treatment: 1,30 + or - 1,30 log copies/mL. The virus load decreasing significantly with p 0,01. There are 72,7 percent of patients with the virus load indetectable at the 48thweek. Especially there is 1,5 percent patient lost HBsAg and there isn't any indesirable side effects due to the drug reaction. Conclusions: Tenofovir is the efficacy drug in the treatment chronic hepatitis B with HBeAg(-). The clinical signs such as asthenia, lost appetite, jaundice decreasing rapidly after 12weeks of treatment. The transaminase enzymes and bilirubinemia become normal after 48 weeks of treatment, the proportion of HBV DNA negative: 72,7 percent. The side effect of drug is rare and mild and there isn't any resistant cases.